

5. Literaturverzeichnis

1. Janeway CA, Jr., Medzhitov R. Innate immune recognition. *Annu Rev Immunol* 2002;20:197-216.
2. Clark R, Kupper T. Old meets new: the interaction between innate and adaptive immunity. *J Invest Dermatol* 2005;125(4):629-37.
3. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. *Nature* 1994;372(6501):100-3.
4. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. *Nature* 1974;248(450):701-2.
5. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. *Cell* 1986;44(6):959-68.
6. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. *Nature* 1987;329(6139):512-8.
7. Rotzschke O, Falk K, Deres K, et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. *Nature* 1990;348(6298):252-4.
8. Van Bleek GM, Nathenson SG. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. *Nature* 1990;348(6298):213-6.
9. Fremont DH, Rees WA, Kozono H. Biophysical studies of T-cell receptors and their ligands. *Curr Opin Immunol* 1996;8(1):93-100.
10. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. *Adv Immunol* 1979;27:51-177.
11. Schwartz RN. The role of gene products of the major histocompatibility complex in T cell activation and cellular interactions. In: Paul WE, ed. *Fundamental Immunology*. New York: Raven Press; 1984:385-92.
12. Cantor H, Boyse EA. Functional subclasses of T lymphocytes bearing different Ly antigens. II. Cooperation between subclasses of Ly⁺ cells in the generation of killer activity. *J Exp Med* 1975;141(6):1390-9.

13. Zinkernagel RM, Doherty PC. H-2 compatibility requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D. *J Exp Med* 1975;141(6):1427-36.
14. Unanue ER. Antigen-presenting function of the macrophage. *Annu Rev Immunol* 1984;2:395-428.
15. Morrison LA, Lukacher AE, Braciale VL, Fan DP, Braciale TJ. Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. *J Exp Med* 1986;163(4):903-21.
16. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. *Nature* 1993;361(6410):359-62.
17. Song R, Harding CV. Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. *J Immunol* 1996;156(11):4182-90.
18. Rock KL. A new foreign policy: MHC class I molecules monitor the outside world. *Immunol Today* 1996;17(3):131-7.
19. Goldberg AL, Rock KL. Proteolysis, proteasomes and antigen presentation. *Nature* 1992;357(6377):375-9.
20. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell* 1994;78(5):761-71.
21. Lehner PJ, Cresswell P. Processing and delivery of peptides presented by MHC class I molecules. *Curr Opin Immunol* 1996;8(1):59-67.
22. Shepherd JC, Schumacher TN, Ashton-Rickardt PG, et al. TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. *Cell* 1993;74(3):577-84.
23. Momburg F, Neefjes JJ, Hammerling GJ. Peptide selection by MHC-encoded TAP transporters. *Curr Opin Immunol* 1994;6(1):32-7.
24. Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for the recognition of peptide antigens by MHC class I molecules. *Science* 1992;257(5072):927-34.
25. Dick TP, Ruppert T, Groettrup M, et al. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. *Cell* 1996;86(2):253-62.

26. Davidson HW, Reid PA, Lanzavecchia A, Watts C. Processed antigen binds to newly synthesized MHC class II molecules in antigen-specific B lymphocytes. *Cell* 1991;67(1):105-16.
27. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. *Cell* 1995;82(1):155-65.
28. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA, Jr. Sequence analysis of peptides bound to MHC class II molecules. *Nature* 1991;353(6345):622-7.
29. Chicz RM, Urban RG, Lane WS, et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. *Nature* 1992;358(6389):764-8.
30. Srinivasan M, Domanico SZ, Kaumaya PT, Pierce SK. Peptides of 23 residues or greater are required to stimulate a high affinity class II-restricted T cell response. *Eur J Immunol* 1993;23(5):1011-6.
31. Oldstone MB. Molecular mimicry and autoimmune disease. *Cell* 1987;50(6):819-20.
32. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. *Science* 1994;265(5168):106-9.
33. Keat A. Reiter's syndrome and reactive arthritis in perspective. *N Engl J Med* 1983;309(26):1606-15.
34. Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. *Arthritis Rheum* 1991;34(1):6-14.
35. Sieper J, Fendler C, Laitko S, et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. *Arthritis Rheum* 1999;42(7):1386-96.
36. Sieper J, Kingsley G. Recent advances in the pathogenesis of reactive arthritis. *Immunol Today* 1996;17(4):160-3.
37. Brewerton DA, Caffrey M, Nicholls A, Walters D, Oates JK, James DC. Reiter's disease and HL-A 27. *Lancet* 1973;2(7836):996-8.
38. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. *Arthritis Rheum* 1991;34(10):1218-27.

39. Reiter H. Ueber eine bisher unbekannte Spirochäteninfektion (Spirochaetosis Arthritica). *Dtsch Med Wochenschr* 1916;42:1535-6.
40. Brodie BC. Pathological and surgical observations on diseases of the joints. In. London: Longman; 1818:51-63.
41. Granfors K, Jalkanen S, von Essen R, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. *N Engl J Med* 1989;320(4):216-21.
42. Granfors K, Jalkanen S, Lindberg AA, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. *Lancet* 1990;335(8691):685-8.
43. Granfors K, Jalkanen S, Toivanen P, Koski J, Lindberg AA. Bacterial lipopolysaccharide in synovial fluid cells in Shigella triggered reactive arthritis. *J Rheumatol* 1992;19(3):500.
44. Bas S, Griffais R, Kvien TK, Glennas A, Melby K, Vischer TL. Amplification of plasmid and chromosome Chlamydia DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies. *Arthritis Rheum* 1995;38(7):1005-13.
45. Ford DK, da Roza DM, Shah P, Wenman WM. Cell-mediated immune responses of synovial mononuclear cells in Reiter's syndrome against ureaplasma and chlamydial antigens. *J Rheumatol* 1980;7(5):751-5.
46. Gaston JS, Life PF, Granfors K, et al. Synovial T lymphocyte recognition of organisms that trigger reactive arthritis. *Clin Exp Immunol* 1989;76(3):348-53.
47. Sieper J, Kingsley G, Palacios-Boix A, et al. Synovial T lymphocyte-specific immune response to Chlamydia trachomatis in Reiter's disease. *Arthritis Rheum* 1991;34(5):588-98.
48. Toivanen A. Reactive arthritis: clinical features and treatment. In: Hochberg MC, Silman, A. J., Smolen, J. et al, ed. *Rheumatology*. 3rd edition ed: Mosby; 2003:1233-40.
49. Keat AC, Maini RN, Nkwazi GC, Pegrum GD, Ridgway GL, Scott JT. Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. *Br Med J* 1978;1(6113):605-7.
50. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. *Rheum Dis Clin North Am* 1998;24(4):737-51, viii.
51. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. *Lancet* 1973;1(7809):904-7.
52. Sansonetti PJ, d'Hauteville H, Ecobichon C, Pourcel C. Molecular comparison of virulence plasmids in Shigella and enteroinvasive Escherichia coli. *Ann Microbiol (Paris)* 1983;134A(3):295-318.

53. Sansonetti PJ, Hale TL, Dammin GJ, Kapfer C, Collins HH, Jr., Formal SB. Alterations in the pathogenicity of *Escherichia coli* K-12 after transfer of plasmid and chromosomal genes from *Shigella flexneri*. *Infect Immun* 1983;39(3):1392-402.
54. Pupo GM, Lan R, Reeves PR. Multiple independent origins of *Shigella* clones of *Escherichia coli* and convergent evolution of many of their characteristics. *Proc Natl Acad Sci U S A* 2000;97(19):10567-72.
55. Jin Q, Yuan Z, Xu J, et al. Genome sequence of *Shigella flexneri* 2a: insights into pathogenicity through comparison with genomes of *Escherichia coli* K12 and O157. *Nucleic Acids Res* 2002;30(20):4432-41.
56. Takeuchi A, Sprinz H, LaBrec EH, Formal SB. Experimental bacillary dysentery. An electron microscopic study of the response of the intestinal mucosa to bacterial invasion. *Am J Pathol* 1965;47(6):1011-44.
57. Mathan MM, Mathan VI. Morphology of rectal mucosa of patients with shigellosis. *Rev Infect Dis* 1991;13 Suppl 4:S314-8.
58. Islam D, Veress B, Bardhan PK, Lindberg AA, Christensson B. In situ characterization of inflammatory responses in the rectal mucosae of patients with shigellosis. *Infect Immun* 1997;65(2):739-49.
59. DuPont HL, Hornick RB, Dawkins AT, Snyder MJ, Formal SB. The response of man to virulent *Shigella flexneri* 2a. *J Infect Dis* 1969;119(3):296-9.
60. Waterman SR, Small PL. Identification of sigma S-dependent genes associated with the stationary-phase acid-resistance phenotype of *Shigella flexneri*. *Mol Microbiol* 1996;21(5):925-40.
61. Mounier J, Vasselon T, Hellio R, Lesourd M, Sansonetti PJ. *Shigella flexneri* enters human colonic Caco-2 epithelial cells through the basolateral pole. *Infect Immun* 1992;60(1):237-48.
62. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. *Cell* 1996;86(3):345-8.
63. Zychlinsky A, Prevost MC, Sansonetti PJ. *Shigella flexneri* induces apoptosis in infected macrophages. *Nature* 1992;358(6382):167-9.
64. Zychlinsky A, Thirumalai K, Arondel J, Cantey JR, Aliprantis AO, Sansonetti PJ. In vivo apoptosis in *Shigella flexneri* infections. *Infect Immun* 1996;64(12):5357-65.

65. Perdomo JJ, Gounon P, Sansonetti PJ. Polymorphonuclear leukocyte transmigration promotes invasion of colonic epithelial monolayer by *Shigella flexneri*. *J Clin Invest* 1994;93(2):633-43.
66. Vasselon T, Mounier J, Prevost MC, Hellio R, Sansonetti PJ. Stress fiber-based movement of *Shigella flexneri* within cells. *Infect Immun* 1991;59(5):1723-32.
67. Bernardini ML, Mounier J, d'Hauteville H, Coquis-Rondon M, Sansonetti PJ. Identification of *icsA*, a plasmid locus of *Shigella flexneri* that governs bacterial intra- and intercellular spread through interaction with F-actin. *Proc Natl Acad Sci U S A* 1989;86(10):3867-71.
68. Vasselon T, Mounier J, Hellio R, Sansonetti PJ. Movement along actin filaments of the perijunctional area and de novo polymerization of cellular actin are required for *Shigella flexneri* colonization of epithelial Caco-2 cell monolayers. *Infect Immun* 1992;60(3):1031-40.
69. Sansonetti PJ, Mounier J, Prevost MC, Mege RM. Cadherin expression is required for the spread of *Shigella flexneri* between epithelial cells. *Cell* 1994;76(5):829-39.
70. Simon DG, Kaslow RA, Rosenbaum J, Kaye RL, Calin A. Reiter's syndrome following epidemic shigellosis. *J Rheumatol* 1981;8(6):969-73.
71. Finch M, Rodey G, Lawrence D, Blake P. Epidemic Reiter's syndrome following an outbreak of shigellosis. *Eur J Epidemiol* 1986;2(1):26-30.
72. Ekman P, Kirveskari J, Granfors K. Modification of disease outcome in *Salmonella*-infected patients by HLA-B27. *Arthritis Rheum* 2000;43(7):1527-34.
73. Sieper J, Rudwaleit M, Braun J, van der Heijde D. Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. *Arthritis Rheum* 2002;46(2):319-27.
74. Sieper J, Kingsley GH, Marker-Hermann E. Aetiological agents and immune mechanisms in enterogenic reactive arthritis. *Baillieres Clin Rheumatol* 1996;10(1):105-21.
75. Harty JT, Pamer EG. CD8 T lymphocytes specific for the secreted p60 antigen protect against *Listeria monocytogenes* infection. *J Immunol* 1995;154(9):4642-50.
76. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. *Annu Rev Immunol* 2006;24:519-40.
77. Lauhio A, Lahdevirta J, Janes R, Kontiainen S, Repo H. Reactive arthritis associated with *Shigella sonnei* infection. *Arthritis Rheum* 1988;31(9):1190-3.
78. Chen M, Delpech V, O'Sullivan B, Donovan B. *Shigella sonnei*: another cause of sexually acquired reactive arthritis. *Int J STD AIDS* 2002;13(2):135-6.

79. Kaslow RA, Ryder RW, Calin A. Search for Reiter's syndrome after an outbreak of *Shigella sonnei* dysentery. *J Rheumatol* 1979;6(5):562-6.
80. Stieglitz H, Fosmire S, Lipsky P. Identification of a 2-Md plasmid from *Shigella flexneri* associated with reactive arthritis. *Arthritis Rheum* 1989;32(8):937-46.
81. Stieglitz H, Lipsky P. Association between reactive arthritis and antecedent infection with *Shigella flexneri* carrying a 2-Md plasmid and encoding an HLA-B27 mimetic epitope. *Arthritis Rheum* 1993;36(10):1387-91.
82. Adam T, Siewerdt R, Offermann I, et al. Prevalence and molecular diversity of pHS-2 plasmids, marker for arthritogenicity, among clinical *Escherichia coli* *Shigella* isolates. *Microbes Infect* 2003;5(7):579-92.
83. Rolland K, Lambert-Zechovsky N, Picard B, Denamur E. *Shigella* and enteroinvasive *Escherichia coli* strains are derived from distinct ancestral strains of *E. coli*. *Microbiology* 1998;144 (Pt 9):2667-72.
84. Hammer M, Nettelbreker E, Hopf S, Schmitz E, Porschke K, Zeidler H. Chlamydial rRNA in the joints of patients with Chlamydia-induced arthritis and undifferentiated arthritis. *Clin Exp Rheumatol* 1992;10(1):63-6.
85. Burmester GR, Daser A, Kamradt T, et al. Immunology of reactive arthritides. *Annu Rev Immunol* 1995;13:229-50.
86. Braun J, Tuszewski M, Ehlers S, et al. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. *J Rheumatol* 1997;24(6):1101-5.
87. Lindberg AA, Cam PD, Chan N, et al. Shigellosis in Vietnam: seroepidemiologic studies with use of lipopolysaccharide antigens in enzyme immunoassays. *Rev Infect Dis* 1991;13 Suppl 4:S231-7.
88. Allaoui A, Sansonetti PJ, Menard R, et al. MxiG, a membrane protein required for secretion of *Shigella* spp. Ipa invasins: involvement in entry into epithelial cells and in intercellular dissemination. *Mol Microbiol* 1995;17(3):461-70.
89. Gerard HC, Branigan PJ, Schumacher HR, Jr., Hudson AP. Synovial *Chlamydia trachomatis* in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. *J Rheumatol* 1998;25(4):734-42.

90. Sansonetti PJ, Kopecko DJ, Formal SB. Involvement of a plasmid in the invasive ability of *Shigella flexneri*. *Infect Immun* 1982;35(3):852-60.
91. Petrovskaya VG, Bondarenko VM. Recommended corrections to the classification of *Shigella flexneri* on a genetic basis. *Int J Syst Bacteriol* 1977;27:171-5.
92. Rahman MU, Cheema MA, Schumacher HR, Hudson AP. Molecular evidence for the presence of chlamydia in the synovium of patients with Reiter's syndrome. *Arthritis Rheum* 1992;35(5):521-9.
93. Sieper J, Braun J. Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? *Arthritis Rheum* 1995;38(11):1547-54.
94. Geczy AF, Alexander K, Bashir HV, Edmonds JP, Upfold L, Sullivan J. HLA-B27, *Klebsiella* and ankylosing spondylitis: biological and chemical studies. *Immunol Rev* 1983;70:23-50.
95. Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. *Immunol Today* 1990;11(4):137-42.
96. Scofield RH, Warren WL, Koelsch G, Harley JB. A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution. *Proc Natl Acad Sci U S A* 1993;90(20):9330-4.
97. Scofield RH, Kurien B, Gross T, Warren WL, Harley JB. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. *Lancet* 1995;345(8964):1542-4.
98. Parham P. Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated arthritis. *Immunol Rev* 1996;154:137-54.
99. Wilson CS, Moser JM, Altman JD, Jensen PE, Lukacher AE. Cross-recognition of two middle T protein epitopes by immunodominant polyoma virus-specific CTL. *J Immunol* 1999;162(7):3933-41.
100. Misko IS, Cross SM, Khanna R, et al. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. *Proc Natl Acad Sci U S A* 1999;96(5):2279-84.
101. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC. *Cell* 1992;70(6):1035-48.

102. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. *J Exp Med* 1994;180(6):2359-64.
103. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. *Lancet* 1993;342(8872):646-50.
104. Khare SD, Luthra HS, David CS. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies. *J Exp Med* 1995;182(4):1153-8.
105. Khare SD, Bull MJ, Hanson J, Luthra HS, David CS. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. *J Immunol* 1998;160(1):101-6.
106. Allen RL, O'Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. *J Immunol* 1999;162(9):5045-8.
107. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature* 1991;351(6324):290-6.
108. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. *Nature* 1991;353(6342):326-9.
109. Marker-Hermann E, Meyer zum Buschenfelde KH, Wildner G. HLA-B27-derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis. *Arthritis Rheum* 1997;40(11):2047-54.
110. Horwitz MA, Lee BW, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* 1995;92(5):1530-4.
111. Buchmeier NA, Heffron F. Induction of *Salmonella* stress proteins upon infection of macrophages. *Science* 1990;248(4956):730-2.
112. Shinnick TM, Vodkin MH, Williams JC. The *Mycobacterium tuberculosis* 65-kilodalton antigen is a heat shock protein which corresponds to common antigen and to the *Escherichia coli* GroEL protein. *Infect Immun* 1988;56(2):446-51.
113. Vodkin MH, Williams JC. A heat shock operon in *Coxiella burnetii* produces a major antigen homologous to a protein in both mycobacteria and *Escherichia coli*. *J Bacteriol* 1988;170(3):1227-34.

114. Hoffmann GR, Freemer CS, Parente LA. Induction of genetic duplications and frameshift mutations in *Salmonella typhimurium* by acridines and acridine mustards: dependence on covalent binding of the mutagen to DNA. *Mol Gen Genet* 1989;218(3):377-83.
115. Probst P, Hermann E, Meyer zum Buschenfelde KH, Fleischer B. Multiclonal synovial T cell response to *Yersinia enterocolitica* in reactive arthritis: the *Yersinia* 61-kDa heat-shock protein is not the major target antigen. *J Infect Dis* 1993;167(2):385-91.
116. Ugrinovic S, Mertz A, Wu P, Braun J, Sieper J. A single nonamer from the *Yersinia* 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in *Yersinia*-induced reactive arthritis. *J Immunol* 1997;159(11):5715-23.
117. Mertz AK, Ugrinovic S, Lauster R, et al. Characterization of the synovial T cell response to various recombinant *Yersinia* antigens in *Yersinia enterocolitica*-triggered reactive arthritis. Heat-shock protein 60 drives a major immune response. *Arthritis Rheum* 1998;41(2):315-26.
118. Sieper J. Pathogenesis of reactive arthritis. *Curr Rheumatol Rep* 2001;3(5):412-8.
119. van Roon JA, van Eden W, van Roy JL, Lafeber FJ, Bijlsma JW. Stimulation of suppressive T cell responses by human but not bacterial 60-kD heat-shock protein in synovial fluid of patients with rheumatoid arthritis. *J Clin Invest* 1997;100(2):459-63.
120. van der Zee R, Anderton SM, Prakken AB, Liesbeth Paul AG, van Eden W. T cell responses to conserved bacterial heat-shock-protein epitopes induce resistance in experimental autoimmunity. *Semin Immunol* 1998;10(1):35-41.
121. Elkon KB, Parnassa AP, Foster CL. Lupus autoantibodies target ribosomal P proteins. *J Exp Med* 1985;162(2):459-71.
122. Elkon K, Skelly S, Parnassa A, et al. Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. *Proc Natl Acad Sci U S A* 1986;83(19):7419-23.
123. Mertz AK, Batsford SR, Curschellas E, Kist MJ, Gondolf KB. Cationic *Yersinia* antigen-induced chronic allergic arthritis in rats. A model for reactive arthritis in humans. *J Clin Invest* 1991;88(2):632-42.
124. Mertz AK, Daser A, Skurnik M, et al. The evolutionarily conserved ribosomal protein L23 and the cationic urease beta-subunit of *Yersinia enterocolitica* O:3 belong to the immunodominant antigens in *Yersinia*-triggered reactive arthritis: implications for autoimmunity. *Mol Med* 1994;1(1):44-55.

125. Mayer C, Appenzeller U, Seelbach H, et al. Humoral and cell-mediated autoimmune reactions to human acidic ribosomal P2 protein in individuals sensitized to *Aspergillus fumigatus* P2 protein. *J Exp Med* 1999;189(9):1507-12.
126. Villanueva MS, Fischer P, Feen K, Pamer EG. Efficiency of MHC class I antigen processing: a quantitative analysis. *Immunity* 1994;1(6):479-89.
127. Sijts AJ, Pamer EG. Enhanced intracellular dissociation of major histocompatibility complex class I-associated peptides: a mechanism for optimizing the spectrum of cell surface-presented cytotoxic T lymphocyte epitopes. *J Exp Med* 1997;185(8):1403-11.
128. Vijh S, Pamer EG. Immunodominant and subdominant CTL responses to *Listeria monocytogenes* infection. *J Immunol* 1997;158(7):3366-71.
129. van den Berg WB, van de Putte LB, Zwarts WA, Joosten LA. Electrical charge of the antigen determines intraarticular antigen handling and chronicity of arthritis in mice. *J Clin Invest* 1984;74(5):1850-9.
130. van Lent PL, van den Bersselaar L, Grutters GJ, van den Berg WB. Fate of antigen after intravenous and intraarticular injection into mice. Role of molecular weight and charge. *J Rheumatol* 1989;16(10):1295-303.
131. van Lent PL, Dekker C, Mosterd J, van den Bersselaar L, van den Berg WB. Allergic arthritis induced by cationic proteins: role of molecular weight. *Immunology* 1989;67(4):447-52.
132. Kaltschmidt E, Wittmann HG. Ribosomal proteins. VII. Two-dimensional polyacrylamide gel electrophoresis for fingerprinting of ribosomal proteins. *Anal Biochem* 1970;36(2):401-12.
133. Geyl D, Bock A, Isono K. An improved method for two-dimensional gel-electrophoresis: analysis of mutationally altered ribosomal proteins of *Escherichia coli*. *Mol Gen Genet* 1981;181(3):309-12.
134. Brockmoller J, Kamp RM. Two-dimensional polyacrylamide gel electrophoresis of ribosomal proteins in the nanogram range. *Biol Chem Hoppe Seyler* 1985;366(9):901-6.
135. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci U S A* 1979;76(9):4350-4.
136. Vanatalu K, Paalme T, Vilu R, et al. Large-scale preparation of fully deuterated cell components. Ribosomes from *Escherichia coli* with high biological activity. *Eur J Biochem* 1993;216(1):315-21.

137. Bommer U, Burkhardt N, Jünemann R, Spahn CMT, Triana-Alonso FJ, Nierhaus KH. Ribosomes and polysomes. Oxford: IRL Press at Oxford University Press; 1996.
138. Diedrich G, Burkhardt N, Nierhaus KH. Large-scale isolation of proteins of the large subunit from *Escherichia coli* ribosomes. *Protein Expr Purif* 1997;10(1):42-50.
139. Kamp RM, Bosserhoff A, Kamp D, Wittmann-Liebold B. Application of high-performance liquid chromatographic techniques to the separation of ribosomal proteins of different organisms. *J Chromatogr* 1984;317:181-92.
140. Zhou M, Sayad A, Simmons WA, et al. The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. *J Exp Med* 1998;188(5):877-86.
141. Khare SD, Lee S, Bull MJ, et al. Peptide binding alpha1alpha2 domain of HLA-B27 contributes to the disease pathogenesis in transgenic mice. *Hum Immunol* 1999;60(2):116-26.
142. Buxton SE, Benjamin RJ, Clayberger C, Parham P, Krensky AM. Anchoring pockets in human histocompatibility complex leukocyte antigen (HLA) class I molecules: analysis of the conserved B ("45") pocket of HLA-B27. *J Exp Med* 1992;175(3):809-20.
143. Fiorillo MT, Maragno M, Butler R, Dupuis ML, Sorrentino R. CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. *J Clin Invest* 2000;106(1):47-53.
144. D'Amato M, Fiorillo MT, Carcassi C, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. *Eur J Immunol* 1995;25(11):3199-201.
145. Fiorillo MT, Greco G, Maragno M, et al. The naturally occurring polymorphism Asp116-->His116, differentiating the ankylosing spondylitis-associated HLA-B*2705 from the non-associated HLA-B*2709 subtype, influences peptide-specific CD8 T cell recognition. *Eur J Immunol* 1998;28(8):2508-16.
146. Diedrich G. Eine Funktionsanalyse des ribosomalen Proteins L2 von *Escherichia coli*. Berlin: Technische Universität Berlin; 1997.
147. Kramer G, Rauch T, Rist W, et al. L23 protein functions as a chaperone docking site on the ribosome. *Nature* 2002;419(6903):171-4.
148. Wilson DN, Nierhaus KH. Ribosomal proteins in the spotlight. *Crit Rev Biochem Mol Biol* 2005;40(5):243-67.
149. Nowotny V, Nierhaus KH. Initiator proteins for the assembly of the 50S subunit from *Escherichia coli* ribosomes. *Proc Natl Acad Sci U S A* 1982;79(23):7238-42.

150. Nissen P, Hansen J, Ban N, Moore PB, Steitz TA. The structural basis of ribosome activity in peptide bond synthesis. *Science* 2000;289(5481):920-30.
151. Probst P, Hermann E, Meyer zum Buschenfelde KH, Fleischer B. Identification of the *Yersinia enterocolitica* urease beta subunit as a target antigen for human synovial T lymphocytes in reactive arthritis. *Infect Immun* 1993;61(10):4507-9.
152. Ringrose JH, Muijsers AO, Pannekoek Y, et al. Influence of infection of cells with bacteria associated with reactive arthritis on the peptide repertoire presented by HLA-B27. *J Med Microbiol* 2001;50(4):385-9.
153. Wildner G, Thureau SR. Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. *Eur J Immunol* 1994;24(11):2579-85.
154. Thureau SR, Diedrichs-Mohring M, Fricke H, Burchardi C, Wildner G. Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. *Immunol Lett* 1999;68(2-3):205-12.
155. Thureau SR, Fricke H, Burchardi C, Diedrichs-Mohring M, Wildner G. Long-term follow-up of oral tolerance induction with HLA-peptide B27PD in patients with uveitis. *Ann N Y Acad Sci* 2004;1029:408-12.
156. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. *Ann Rheum Dis* 2000;59(7):565-70.
157. Kvien TK, Gaston JS, Bardin T, et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. *Ann Rheum Dis* 2004;63(9):1113-9.
158. Oili KS, Niinisalo H, Korpilahde T, Virolainen J. Treatment of reactive arthritis with infliximab. *Scand J Rheumatol* 2003;32(2):122-4.
159. Haibel H, Brandt J, Rudwaleit M, Braun J, Sieper J. Therapy of chronic enteral reactive arthritis with infliximab. *Ann Rheum Dis* 2003;62(supplement 1):470.
160. Haibel H, Rudwaleit M, Sieper J, Zeidler H, Kuipers JG. [Diagnosis of reactive arthritis]. *Z Rheumatol* 2004;63(3):211-5.
161. Kaluza W, Meyer zum Buschenfelde KH, Galle PR, Marker-Hermann E. Synovial fluid lymphocyte proliferation in response to crude microbial antigens is not useful as a diagnostic test to specifically indicate a bacterial cause of arthritis. *Clin Exp Rheumatol* 2000;18(1):39-46.

162. Appel H, Rudwaleit M, Wu P, Grolms M, Sieper J, Mertz A. Synovial T cell proliferation to the *Yersinia enterocolitica* 19 kDa antigen differentiates yersinia triggered reactive arthritis (ReA) from ReA triggered by other enterobacteria. *Ann Rheum Dis* 2002;61(6):566-7.
163. Blattner FR, Plunkett G, 3rd, Bloch CA, et al. The complete genome sequence of *Escherichia coli* K-12. *Science* 1997;277(5331):1453-74.
164. Ellenberger DL, Lammie PJ. Immunologic characterization of jird lymphocyte responsiveness to *Brugia pahangi* ribosomal protein S13. *Exp Parasitol* 1992;75(3):293-302.
165. Shi Y, Zhai H, Wang X, et al. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. *Exp Cell Res* 2004;296(2):337-46.
166. Atagunduz P, Appel H, Kuon W, et al. HLA-B27-restricted CD8⁺ T cell response to cartilage-derived self peptides in ankylosing spondylitis. *Arthritis Rheum* 2005;52(3):892-901.